文献速递胸部CT

基于CT影像与免疫分型预测非小细胞肺癌术后辅助化疗持久临床获益的列线图

Predicting Durable Clinical Benefits of Postoperative Adjuvant Chemotherapy in Non-small Cell Lung Cancer: A Nomogram Based on CT Imaging and Immune Type.
PubMed 文献 · Acad Radiol · 2024-08-16

研究纳入205例术前行CT检查的非小细胞肺癌患者,按无进展生存期≥18个月(DCB组118例)或<18个月(NDCB组87例)分组,量化PD-L1与CD8+TIL密度百分位评估肿瘤微环境免疫分型(TIMT),结合临床特征和常规CT征象构建列线图,联合模型AUC为0.70(95%CI: 0.64-0.76),敏感度0.73、特异度0.60。

要点

  • 联合模型纳入TIMT、cM分期、淋巴细胞计数和胸腔积液,AUC为0.70(95%CI: 0.64-0.76)。
  • 常规CT征象中,胸膜牵拉、空泡样透亮区、最大径和静脉期CT值在四个TIMT组间有差异(P<0.05)。
  • DCB组与NDCB组间空泡样透亮区和胸腔积液有差异(P<0.05)。

核心结论

  • 常规CT征象与肿瘤微环境免疫分型联合,为预测非小细胞肺癌术后辅助化疗患者的临床结局提供了有前景的方法。

研究设计与样本

  • 共205例非小细胞肺癌患者术前行CT检查,分为DCB组(PFS≥18个月,118例)和NDCB组(PFS<18个月,87例),量化PD-L1与CD8+TIL密度百分位评估TIMT,采用多变量logistic回归构建预测模型并绘制列线图。

关键影像表现/征象

  • 常规CT征象(毛刺征、空泡样透亮区、胸膜牵拉、最大径、静脉期CT值)在四个TIMT组间差异有统计学意义(P<0.05);空泡样透亮区和胸腔积液在DCB与NDCB组间差异有统计学意义(P<0.05)。

诊断标准与关键数值

  • DCB定义为无进展生存期≥18个月,NDCB定义为无进展生存期<18个月;联合模型AUC为0.70(95%CI: 0.64-0.76),敏感度0.73,特异度0.60。

临床应用与阅片要点

  • 多变量分析显示TIMT、cM分期、淋巴细胞计数和胸腔积液与DCB独立相关,并用于构建列线图。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: To develop a model based on conventional CT signs and the tumor microenvironment immune types (TIMT) to predict the durable clinical benefits (DCB) of postoperative adjuvant chemotherapy in non-small cell lung cancer (NSCLC).

METHODS AND MATERIALS: A total of 205 patients with NSCLC underwent preoperative CT and were divided into two groups: DCB (progression-free survival (PFS) ≥ 18 months) and non-DCB (NDCB, PFS <18 months). The density percentiles of PD-L1 and CD8 + tumor-infiltrating lymphocytes (TIL) were quantified to estimate the TIMT. Clinical characteristics and conventional CT signs were collected. Multivariate logistic regression was employed to select the most discriminating parameters, construct a predictive model, and visualize the model as a nomogram. Receiver operating characteristic (ROC) curves, calibration curves, and decision curve analysis (DCA) were used to evaluate prediction performance and clinical utility.

RESULTS: Precisely 118 patients with DCB and 87 with NDCB in NSCLC received postoperative adjuvant chemotherapy. TIMT was statistically different between the DCB and NDCB groups (P < 0.05). Clinical characteristics (neuron-specific enolase, squamous cell carcinoma antigen, Ki-76, and cM stage) and conventional CT signs (spiculation, bubble-like lucency, pleural retraction, maximum diameter, and CT value of the venous phase) varied between the four TIMT groups (P < 0.05). Furthermore, clinical characteristics (lymphocyte count [LYMPH] and cM stage) and conventional CT signs (bubble-like lucency and Pleural effusion) differed between the DCB and NDCB groups (P < 0.05). Multivariate analysis revealed that TIMT, cM stage, LYMPH, and pleural effusion were independently associated with DCB and were used to construct a nomogram. The area under the curve (AUC) of the combined model was 0.70 (95%CI: 0.64-0.76), with sensitivity and specificity of 0.73 and 0.60, respectively.

CONCLUSION: Conventional CT signs and the TIMT offer a promising approach to predicting clinical outcomes for patients treated with postoperative adjuvant chemotherapy in NSCLC.

来源:Acad Radiol,查看原文。版权归原作者所有。

引用

  1. Deng L, Zhang M, Zhu K, et al. Predicting Durable Clinical Benefits of Postoperative Adjuvant Chemotherapy in Non-small Cell Lung Cancer: A Nomogram Based on CT Imaging and Immune Type. Acad Radiol. 2024. PMID: 39153960. doi:10.1016/j.acra.2024.07.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。